Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | CD44 | P16070 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133713 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA4CHRNA2HTR2A | |
| SCHEMBL21326130 | 0.93 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA4CHRNA2HTR2A | |
| Hydrochloric Acid SCHEMBL25324792 | 0.92 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA4CHRNA2DRD2 | |
| SCHEMBL29640882 | 0.85 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL10067119 | 0.77 | ASIC3 (0.43) | HTR2CHTR2BASIC3DRD2DRD3 | |
| SCHEMBL7238336 | 0.76 | NOS3 (0.50) | CHRNB2CHRNB4CHRNA4CHRNA2HTR2A | |
| SCHEMBL27884524 | 0.76 | NOS3 (0.45) | CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL17892754 | 0.74 | RYR2 (0.56) | CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL1721036 | 0.74 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA4CHRNA2DRD2 | |
| SCHEMBL3034518 | 0.74 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA4CHRNA2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| EP-4174066-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-05-03 | — | — | EP | disclosed |
| CN-115605475-A | Immunosuppressant, preparation method and application thereof | 上海和誉生物医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| WO-2021254005-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2021-12-23 | — | — | WO | disclosed |
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | disclosed |
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| EP-3240537-B1 | NOVEL TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2020-09-09 | — | — | EP | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-02-07 | — | — | US | disclosed |
| EP-1831196-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831199-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065215-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065216-A1 | NOVEL HYDANTOIN DERIVATIVES AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552811-B2 | Immunosuppressant, and preparation method therefor and use thereof | CD274, PDCD1, PDCD1LG2 | CHRNB2 4069/4885CHRNB4 4084/4885CHRNA4 3082/4885 |
| US-20080032997-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | CHRNB2 4301/4885CHRNB4 4609/4885CHRNA4 4597/4885 |
| US-20230234970-A1 | IMMUNOSUPPRESSANT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CD274, PDCD1, PDCD1LG2 | CHRNB2 4877/4885CHRNB4 4879/4885CHRNA4 4864/4885 |
| US-20080293743-A1 | Novel Hydantoin Derivatives as Metalloproteinase Inhibitors | MMP1, MMP2, MMP9 | CHRNB2 4301/4885CHRNB4 4609/4885CHRNA4 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.